drugset / Trial / NCT03490903

Coronary Angiography THerapeutic Virtual Reality

NCT03490903 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The CATH-VR study will investigate the effect of virtual reality (VR) on patient pain, anxiety, and radial artery vasospasm during coronary angiography. Our hypothesis is that the use of VR will decrease patient anxiety and pain via validated scoring systems, as well as show a low rate of vasospasm of the radial artery. In addition, we hypothesize that the amount of opioid and benzodiazepine medications utilized for procedural sedation will be lower in the intervention arm. VR has gained recent attraction as an alternative or adjunctive treatment option for pain, but its effect on reducing procedural sedation has not been studied. We propose a single center, randomized control pilot study to further investigate. The patient population will include adults older than 18 years who present for outpatient diagnostic coronary angiography.

Timeline

Start
2018-06-01
Primary completion
2018-06-30
Completion
2018-06-30

Outcome

Outcome not reported

Stopped (Enrollment): “No patients enrolled”

Drugs

EvaluationDrugModalityDoseRoute
Background Fentanyl Injection Unknown — Intravenous
Background Midazolam injection Unknown — Intravenous